Here’s our handpicked selection of the best blog posts, popular articles, and breaking biotech news of the last two weeks: Longevity enthusiasts...
This chip can pluck the bad apples out of your blood
Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible ...
James Peyer: Where are stem cell therapies headed?
Someday soon we may be able to replace tissues or entire organs with those grown from a patients’ own stem cells… but just how soon? What ...
Research roundup: Muscles from the lab, and more
We know you want to keep up with the relentless march of progress, but sometimes it’s just too relentless. So why not forget all those endlessly...
Will this protein help speed up clinical trials?
Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s fu...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
Evolution: Pulling doubled lifespan out of a hat
Part III of III in a series on the evolution of aging. (Part I, Part II) If all you had to go on was our genomes, you’d surely conclude that humans an...
What’s new in media and industry: Laura Deming’s intro to longevity, and more
Just getting started around here, or want to introduce someone new to the world of longevity science? This handy primer from Laura Deming (of Longevit...
James Peyer: Navigating the “Biotech Valley of Death”
Ever hear about an exciting discovery in the biomedical world, then later wonder why it seemingly dropped off the face of the Earth? In fact, it’...
Are cancer prevention and cellular reprogramming really enemies?
Imagine a physiological love triangle: in one corner, a force with the weight of millions of years of evolutionary programming trained on preventing r...